New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease
The International Journal of Tuberculosis and Lung Disease · 2023
DOI: 10.5588/ijtld.23.0032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2023. Verfasst von P Escalante und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Latent Tuberculosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
TB remains a leading cause of morbidity and mortality worldwide. However, most infected immunocompetent individuals are asymptomatic and only 5–10% of these will eventually develop active TB during their lifetime (typically within 2 years after exposure). Therefore, rapid diagnosis and efficient management of asymptomatic infected individuals who are at the highest risk of progression and transmission remain major clinical and public health challenges. In recent years, there has been important scientific progress in our understanding of the spectrum of asymptomatic Mycobacterium tuberculosis (Mtb) infections that not only includes the dynamic state of latent TB infection (LTBI), but also the preclinical state of incipient and subclinical TB. The latter is possibly as prevalent as symptomatically active TB and potentially contributes to global Mtb transmission in various settings. We summarize the latest developments and current challenges of the existing testing tools for LTBI and describe promising biomarkers and diagnostics for the spectrum of asymptomatic TB. Following the negative results of a recent clinical trial for a biomarker-guided preventive therapy approach, we also suggest some treatment options for incipient TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA, Department of Immunology, Mayo Clinic, Rochester, MN, USA.
- Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Chemistry, University of Michigan, Ann Arbor, MI, USA.
- Hospital General Tijuana, ISESALUD, Clínica y Laboratorio de Tuberculosis, Universidad Autónoma de Baja California, Facultad de Medicina y Psicología, Tijuana, Mexico.
Förderung
- NIAID NIH HHS
Zitieren
APA
Escalante, P., Vadiyala, M. R., Pathakumari, B., Marty, P. K., Van Keulen, V. P., Hilgart, H. R., Meserve, K., Theel, E. S., Peikert, T., Bailey, R. C., & Laniado-Laborin, R. (2023). New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.23.0032
Vancouver
Escalante P, Vadiyala MR, Pathakumari B, Marty PK, Van Keulen VP, Hilgart HR, et al. New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease. The International Journal of Tuberculosis and Lung Disease. 2023. doi:10.5588/ijtld.23.0032
BibTeX
@article{Escalante2023,
author = {Escalante, P and Vadiyala, M R and Pathakumari, B and Marty, P K and Van Keulen, V P and Hilgart, H R and Meserve, K and Theel, E S and Peikert, T and Bailey, R C and Laniado-Laborin, R},
title = {New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2023},
doi = {10.5588/ijtld.23.0032}
}
EUVIMED